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Asthma is a heterogeneous inﬂammatory
disorder of the lung caused principally by
sensitization and exposure to an allergen,
but also inﬂuenced by environmental
factors such as cigarette smoking, stress,
exercise, pollution, respiratory virus
infection and certain respiratory bacteria.
The cardinal features of asthma include
wheeze, shortness of breath, variable
and reversible airway obstruction, air-
way hyperresponsiveness, mucus pro-
duction and airway inﬂammation. Aller-
gic asthma is the most common form
of asthma, caused by sensitization and
exposure via the airways to a number of
innocuous allergens including proteins
from house dust mites, animals, moulds
and tree and grass pollens. Sensitization
and challenge elicits a response from Th2
helper T cells and, through the actions of
interleukin (IL)-4, IL-5 and IL-13, IgE
production, airway eosinophilia, mast
cell activation, mucus production and
airway hyperreactivity ensues. Mild
asthma can be well controlled by inhaled
steroid therapies or inhaled steroid-b2
agonist combinations. However, in mod-
erate to severe asthma, adequate control
frequently cannot be achieved with these
therapies, and new and better treatments
are therefore required.
Asthma exacerbations are acute
attacks of asthma when an otherwise
‘stable’ asthmatic experiences a rapid
increase in symptoms accompanied by
decreased lung function, most often
precipitated by a respiratory virus infec-
tion. Asthma exacerbations are respon-
sible for the vast majority of the morbid-
ity and mortality associated with asthma;
and represent an area not well controlled
by current therapy regimes. The search
for new asthma therapies remains an
intensive area of interest, and the last
10 years have seen a number of novel
therapeutic strategies applied to both
stable asthma and asthma exacerbations,
including new formulations of steroids
and b2 agonists, anti-Th2 cytokine thera-
pies, anti-TNF-a therapies, etc.
The work by Koltsida et al (Koltsida
et al, 2011) in this issue of EMBO
Molecular Medicine is of outstanding
importance in this regard for two rea-
sons. The current study clearly shows
that IL-28A, a newly designated type III
interferon (IFN)-l, an anti-viral cytokine,
can ameliorate the allergic and Th17-
induced inﬂammation that occurs after
sensitization and challenge with aero-
solized allergen in mice, which closely
resembles that seen in allergic asthma in
humans. This data shows that IFN-ls
may have additional properties in addi-
tion to their anti-viral capacity, such that
they may be antagonists of Th2 and Th17
responses and function by inducing the
Th1 polarizing cytokines type II IFN-g
and IL-12. The second noteworthy point
is that asthmatics have recently been
observed to be deﬁcient in type I IFN-b
and type III IFN-ls (Contoli et al, 2006;
Wark et al, 2005), and a deﬁciency in
IFN-ls may increase the severity of virus-
induced asthma exacerbations (Contoli
et al, 2006). Together, these studies
propose a dual importance of IFN-l that
had previously not been demonstrated.
The IFN system is composed of three
types of IFN: the anti-viral type I IFNs
(the single IFN-b and the multiple IFN-
as), the type II IFNs and the type III IFN-
ls. Type II IFN-g is fundamentally
different, has different cell type-speciﬁc
expression patterns, is produced by
leukocytes upon a number of stimuli, is
not strictly limited to virus infection, and
has numerous modes of action. Impor-
tantly, type I IFNs are only induced after
virus infection of a cell or stimulation of
certain cell types with type I IFNs and
speciﬁc Toll-like receptor (TLR) agonists.
The type I IFNs signal through the IFN-a
receptor complex (IFNAR), composed of
the IFNAR1 and IFNAR2 chains. Type I
IFN signalling results in the transcription
of a broad range of anti-viral genes (ISGs)
aiming to eliminate or prevent virus
replication. IFN-as are produced more
readily by leukocytes, with dendritic cells
(DCs) being powerful inducers of IFN-as
upon viral provocation. IFN-b can be
produced by both structural cells and
leukocytes and is often ﬁrst produced at
the site of infection by cells directly
infected by viruses, where it then signals
through IFNAR to induce more of itself
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and the IFN-as. The IFN-ls, including IL-
29 (IFN-l1), IL-28A (IFN-l2) and IL-28B
(IFN-l3) in humans (IL-28A and IL-28B
inmice) have similar anti-viral properties
to the type I IFNs (Meager et al, 2005) as
they induce a similar set of ISGs, but are
thought to be expressed preferentially at
mucosal surfaces and act on epithelial
cells. They use a unique receptor com-
plex composed of IFN-lR1a chain (CRF2-
12 or IL-28Ra in mice) and IL-10Rb chain
(CRF2-4). Previously, the IFN-ls were
thought to be strictly regulated by infec-
tion, although some data support a role in
anti-cancer defense through their anti-
proliferative effects. However, whether
IFN-l are induced directly in cancer in
the absence of infection, or by infection
and cancer together, such as in Hepatitis
B infection and heptocellular carcinoma,
is unclear.
Koltsida and colleagues utilized mice
deﬁcient in the IL-28Ra chain, adminis-
tration of exogenous IL-28A and infec-
tion with adenovirus encoding IL-28A in
a mouse model of sensitization and
challenge to the egg allergen ovalbumin
(OVA) to investigate the role of IFN-ls in
allergic airway inﬂammation. Over-
expression of IL-28A by adenovirus or
administration of recombinant IL-28A to
the airways resulted in reduced Th2
signature cytokines (IL-5 and IL-13),
reduced IL-17, but increased IFN-g
production from mesenteric lymph
node-derived T cell cultures and reduced
eosinophil and neutrophil recruitment to
the airways. Mucous staining was also
reduced and lung function was signiﬁ-
cantly improved compared to OVA
sensitized and challenged control mice.
Interestingly, OVA challenged and sen-
sitized mice also revealed low levels of
IL-28A protein in concentrated BAL ﬂuid,
suggesting IL-28A may be induced as
part of the allergic cascade. The IL-
28Ra/ mice developed strong med-
iastinal lymph node-derived Th2 cyto-
kine and IL-17 responses after OVA
challenge, increased BAL eosinophils
and neutrophils and decreased lung
function. Furthermore, experiments with
DCs showed that the effect of IL-28 is
exerted on CD11cþ DC effector function,
and DCs cultured with IL-28A in vitro
expressed high levels of the pro-Th1
transcription factor T-bet, whereas, DCs
from IL-28A adenovirus-treated mice
polarized T cells to the Th1 rather than
Th2 phenotype. CD11cþ DCs expressed
high levels of IL-28Ra mRNA, while RT-
PCR analysis and immunohistochemis-
try showed that T cells and other
inﬁltrating leukocytes within the airways
did not express IL-28Ra, clearly suggest-
ing that DCs rather than T cells respond
to IL-28 in vivo. Finally, the novel effects
of IL-28A on T cell differentiation were
not observed in IFN-gdeﬁcient or mice
depleted of IL-12 p40, showing that IL-
28A induces Th1 effector function via IL-
12 and IFN-g. These ﬁndings are of
particular importance as IL-28 was pre-
viously believed to be an anti-viral or
anti-cancer cytokine and its powerful
immunomodulatory effects on DCs indi-
cate a wider role for IL-28 in T cell
immunoregulation.
The proto-typical Th1 cytokine is
IFN-g, produced by and responsible for
polarizing Th1 cells and working in an
antagonistic manner to IL-4 and IL-13,
the signature cytokines and inducers of
Th2 cells and their responses. The fact
that IL-28 induces IFN-g and IL-12 and,
therefore, functions in a Th1 polarizing
manner may cause a re-think in the
hierarchal order of T cell polarizing
cytokines. While how IL-28 ﬁts into the
natural order of Th1, Th2 and Th17 cell
development is yet to be thought out in
detail; its role in T cell development in
allergic asthma (in the absence of infec-
tion) is a novel ﬁnding. Of particular
interest is how is IL-28 induced in this
model, by what cell type and in which
anatomical location is the DC receiving
IL-28?While the present study shows that
IL-28 is induced by OVA challenge, and
clearly shows the effects of IL-28 admin-
istration on DC function, the exact
mechanism responsible for IL-28 induc-
tion in this context remains to be
investigated. Further, these studies raise
the question whether this ability of IL-28
is shared by the type I IFN-b or IFN-a.
Early work by Romagnani and colleagues
suggests a similar Th1 skewing potential
of IFN-g and IFN-a (Parronchi et al,
1992), but these studies have not been
followed through to impact on therapy.
While these issues were beyond the
scope of the article by Koltsida et al,
the discovery of IL-28 as an immunor-
egulatory cytokine affecting T cell differ-
entiation is important and could poten-
tially impact on asthma and allergy
treatment.
The ﬁnding that asthmatics are deﬁ-
cient in type I and type III IFNs, with IFN-
ls being important in the pathogenesis of
asthma exacerbations has led to the
proposal that anti-viral IFNs may be
attractive therapies for virus-induced
asthma exacerbations. Indeed, inhaled
type I IFN-b is currently being developed
as a novel therapy for asthma exacerba-
tions, and has recently entered a phase II
clinical trial. The work of Koltsida et al
extends this knowledge and suggests that
such therapeutic approaches may not be
limited to asthma exacerbations, but
could also be efﬁcacious in non-exacer-
bating, stable allergic asthma. The Th2
suppressing and Th1 augmenting ability
of IL-28 in mice has implications for
human asthma and other allergic diseases
such as rhinitis, as it could be used to
dampen down or ameliorate Th2 res-
ponses to speciﬁc allergens. As previously
noted, anti-Th2 cytokine therapy is not a
new approach to allergic asthma; how-
ever, in the past only individual cytokines
have been targeted through, for example,
anti-IL-5 antibodies or IL-4R antagonism
that targets two cytokines IL-4 and IL-13,
which both signal through the IL-4Ra
chain (O’Byrne et al, 2004). While these
therapies yielded mixed results in clinical
trials, IL-28 may offer a subtlety different
approach in that a Th1 inducing cytokine
may effectively combat the effects of all
Th2 cytokines and, thereby, be sufﬁcient
to tip the balance of Th1 over Th2 by
directly modulating DCs that polarize
T cells in the presence of antigen.
In summary, Koltsida et al have
identiﬁed IL-28 as a T cell polarizing
cytokine in models of allergic asthma.
IL-28 acts via CD11cþ DCs, effectively
promoting Th1 and suppressing Th2
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» The work supports the
idea that IL-28 may be a
future therapy for both stable
allergic asthma and for
asthma exacerbations, by its
dual function. . . «
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responses. The work is novel and impor-
tant, and highlights a previously unknown
role for IL-28, a cytokine normally asso-
ciated with the anti-viral response. The
work supports the idea that IL-28 may be a
future therapy for both stable allergic
asthma and for asthma exacerbations, by
its dual function: controlling allergic
asthma through its Th1 modulating ability
and virus-induced asthma exacerbations
through its anti-viral activity.
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